作者
Catherine J Lucas, Peter Galettis, Shuzhen Song, Nadia Solowij, Stephanie E Reuter, Jennifer Schneider, Jennifer H Martin
发表日期
2018/9/1
期刊
Clinical therapeutics
卷号
40
期号
9
页码范围
1442-1447
出版商
Elsevier
简介
Background
Medicinal cannabis is prescribed under the provision of a controlled drug in the Australian Poisons Standard. However, multiple laws must be navigated in order for patients to obtain access and imported products can be expensive. Dose-response information for both efficacy and toxicity pertaining to medicinal cannabis is lacking. The pharmacokinetic properties of cannabis administered by traditional routes has been described but to date, there is no literature on the pharmacokinetic properties of an intraperitoneal cannabinoid emulsion.
Case description
A cachectic 56-year-old female with stage IV ovarian cancer and peritoneal metastases presented to hospital with fevers, abdominal distension and severe pain, vomiting, anorexia, dehydration and confusion. The patient reported receiving an intraperitoneal injection, purported to contain 12 g of mixed cannabinoid (administered by a deregistered …
引用总数
20182019202020212022202320244221333